CTCL Licensing Potential Resminostat is an oral HDAC inhibitor in development for CTCL with a pivotal maintenance study in Europe and Japan. Given CTCL's rarity and high unmet need, this asset offers attractive licensing or co development opportunities for partners seeking a late stage CTCL program or to expand HDAC inhibitor portfolios.

Global Trial Network The RESMAIN trial spans numerous centers across Europe and Japan and targets a rare patient population. This global trial network presents opportunities for CRO partnerships, regional co development, or Asia-Pacific market entry collaborations.

Immuno-Oncology Collaboration Domatinostat is being evaluated in Phase 2 in combination with Avelumab, signaling a strategy toward immuno-oncology. This opens doors for collaboration with IO focused companies on combination regimens, companion diagnostics, or data driven partnerships.

Market Credibility Public market credibility and disclosed funding enable confident partner engagements. 4SC is listed on the Frankfurt Prime Standard and reports credible revenue and funding levels, which can de-risk term sheets and facilitate licensing or co development discussions.

Leadership for BD Leadership stability supports efficient business development. A long tenured CEO and a COO appointed in late 2022 suggest steady leadership and a track record that can accelerate partnership negotiations and execution.